| 4-685 | ਕੇ ਕਿ 名称 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | | 159567 | 跨 港股创新药ETF T+0 | 0.029 | 3.72% | | 159570 | 跨 港股通创新药ETF T+0 | 0.061 | 3.77% | | 520700 | 跨 港股通创新药ETF万家 T+0 | 0.059 | 3.72% | | 159286 | 時 港股通创新药ETF鹏华 T+0 | 0.031 | 3.72% | | 513780 | 跨 港股创新药50ETF T+0 | 0.060 | 3.65% | | 159297 | 跨 港股通创新药ETF南方 T+0 | 0.030 | 3.68% | | 159217 | 陪 港股通创新药ETF工银 T+0 | 0.048 | 3.66% | | 520970 | 0 1 1 6 4 | 0.032 | 3.61% | | 513120 | 跨 港股创新药ETF T+0 | 0.046 | 3.60% | | 520500 | 跨 恒生创新药ETF T+0 | 0.057 | 3.56% | 有分析指 ...

每经AI快讯，石药集团(01093.HK)涨近5%，截至发稿，涨4.7%，报10.24港元，成交额4.86亿港元。 （文章来源：每日经济新闻） ...

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing significant activity, driven by major licensing deals and a shift towards commercialization of innovative drugs, indicating a potential investment opportunity in this space [1][3]. Group 1: Market Activity - Hong Kong pharmaceutical stocks are active, with notable increases in companies like Innovent Biologics, which saw a rise of 7.42% followed by an additional 5% increase, alongside significant gains in other firms such as Zai Lab and CSPC Pharmaceutical [1]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) has shown strong performance, rising over 2% and recovering above the 20-day moving average [1]. Group 2: Licensing Deals - The total transaction scale for China's innovative drug licensing-out reached a record $135.7 billion in 2025, with significant collaborations in January 2026, including deals between CSPC and AstraZeneca ($18.5 billion) and Rongchang and AbbVie ($5.6 billion), highlighting the global value of domestic innovative drug pipelines [1][2]. Group 3: Industry Trends - The innovative drug sector in China is transitioning from "scale accumulation" to "value release," with a focus on commercializing drug pipelines, suggesting a period of performance realization for the industry [3]. - The Hong Kong medical sector is showing strength, with the innovative drug industry chain leading the gains, as evidenced by the performance of the Hong Kong Stock Connect Medical ETF [3]. Group 4: Investment Recommendations - Analysts recommend increasing attention to high-growth and improving expectation sectors within the pharmaceutical industry, as the impact of medical insurance cost control has been fully reflected in market expectations [3][4].

Core Insights - The Hong Kong stock market for innovative drugs is experiencing a strong rally, with the Hong Kong Stock Connect Innovative Drug ETF (159570) rising over 3% and achieving a trading volume exceeding 1.3 billion yuan yesterday and over 1 billion yuan today, bringing its total size to over 25 billion yuan [1][3]. Group 1: Market Performance - The innovative drug sector has seen significant interest, with the ETF's latest scale leading among its peers [1]. - Notable stocks within the ETF, such as Rongchang Biopharmaceutical and Zai Lab, have reported gains exceeding 6%, while others like Innovent Biologics and CSPC Pharmaceutical have also shown strong performance [4][5]. Group 2: Recent Developments - Recent collaborations in the innovative drug sector include a partnership between Fuhong Hanlin and Eisai for the commercialization of the anti-PD-1 monoclonal antibody, with an upfront payment of $75 million and potential milestone payments totaling up to $300 million [3]. - Yunding Xinyao announced the approval of Etrasimod for the treatment of moderate to severe active ulcerative colitis in China, following a $224 million deal for exclusive rights in Greater China and South Korea [3]. - Innovent Biologics has entered a strategic collaboration with Eli Lilly to advance global R&D in oncology and immunology, with an upfront payment of $350 million and potential milestone payments of up to $8.5 billion [3]. Group 3: Analyst Recommendations - Analysts from Kaiyuan Securities suggest increasing allocation to the innovative drug sector, highlighting the valuation attractiveness of quality stocks and the potential for significant returns from companies with strong clinical data and overseas expansion prospects [4]. - The report emphasizes the importance of focusing on innovative drugs that have shown resilience and potential for growth, particularly in the context of upcoming earnings reports in 2025 and early 2026 [6].

该行认为，石药集团此次与阿斯利康的合作围绕公司专有的缓释给药技术平台及多肽药物AI发现平台 展开，公司的长效技术可实现多肽药物的缓释。同时，公司的多肽药物AI发现平台可以针对药物靶点 快速设计及筛选候选分子，并可在药效、选择性与信号偏向性等维度进行系统优化。 石药集团(01093)再涨近5%，截至发稿，涨4.7%，报10.24港元，成交额4.86亿港元。 消息面上，近日，石药集团宣布与阿斯利康就创新长效多肽药物开发签订战略合作与授权协议。东北证 券认为，公司此次与阿斯利康的BD交易金额超预期，高额预付款充分彰显阿斯利康对公司长效多肽与 AI制药技术平台的高度认可与长期看好。此次合作也标志着公司与阿斯利康合作的再升级，有望加速 公司长效多肽药物的全球布局。 ...

该行认为，石药集团此次与阿斯利康的合作围绕公司专有的缓释给药技术平台及多肽药物AI发现平台 展开，公司的长效技术可实现多肽药物的缓释。同时，公司的多肽药物AI发现平台可以针对药物靶点 快速设计及筛选候选分子，并可在药效、选择性与信号偏向性等维度进行系统优化。 消息面上，近日，石药集团宣布与阿斯利康就创新长效多肽药物开发签订战略合作与授权协议。东北证 券认为，公司此次与阿斯利康的BD交易金额超预期，高额预付款充分彰显阿斯利康对公司长效多肽与 AI制药技术平台的高度认可与长期看好。此次合作也标志着公司与阿斯利康合作的再升级，有望加速 公司长效多肽药物的全球布局。 石药集团(01093)再涨近5%，截至发稿，涨4.7%，报10.24港元，成交额4.86亿港元。 ...

Group 1: Market Activity - Hong Kong pharmaceutical stocks remain active, with Innovent Biologics experiencing a significant surge following an $8.85 billion business development deal, rising 5% after a previous 7.42% increase [1][7] - Other companies such as Zai Lab, CSPC Pharmaceutical, and Rongchang Biologics also saw substantial gains [1][7] - The Hong Kong Stock Connect Innovation Drug ETF (520880) rose over 2% during trading, recovering above the 20-day moving average [1][7] Group 2: Industry Trends - The total transaction scale for China's innovative drug license-out reached a record $135.7 billion in 2025, with significant collaborations in January 2026, including a $18.5 billion deal between CSPC and AstraZeneca, and a $5.6 billion deal between Rongchang and AbbVie, highlighting the global value of domestic innovative drug pipelines [9] - The innovative drug sector is transitioning from "scale accumulation" to "value release," with a focus on commercial realization of pipeline expectations [9] - The innovative drug sector has seen a correction over the past two quarters, but many quality stocks now offer attractive valuations, suggesting increased attention is warranted [9] Group 3: Investment Recommendations - Analysts recommend focusing on high-growth and improving expectation sectors within the pharmaceutical industry, as the impact of medical insurance cost control has been fully reflected [11] - The Hong Kong Stock Connect Innovation Drug ETF (520880) and its associated funds are highlighted for their 100% focus on innovative drug research companies, with the top ten weighted stocks accounting for over 73% [11] - The Hong Kong Stock Connect Medical ETF (159137) is suggested for its coverage of innovative medical concepts, including brain-computer interfaces and AI healthcare, while also encompassing leading companies across the entire innovative drug supply chain [11]

Core Viewpoint - Nanotechnology, despite its minuscule scale of 10^-9 meters, holds the potential to break technological barriers and create new productive forces, serving as a cornerstone for advancements in AI, chips, and biomedicine [1] Group 1: Nanotechnology Applications - Almost all upstream industries can benefit from the application of nanomaterials and technologies [2] - The display industry has seen advancements with quantum dot technology, which enhances screen quality and reduces energy consumption [4] - Various products utilizing nanotechnology, such as AR glasses and rapid drug testing devices, are emerging, indicating the broad applicability of nanotechnology in daily life [6] Group 2: Industry Development and Goals - The Guangdong-Hong Kong-Macao Greater Bay Area is focusing on overcoming "bottleneck" technologies and building platforms for concept verification and pilot testing to bridge the gap between laboratory research and market products [1][7] - The goal is to accelerate the industrialization of high-end nanomaterials, supporting future industries like quantum information and precision medicine [7] - The establishment of a national-level innovation platform for nanotechnology aims to enhance collaboration among leading enterprises and support the innovation chain [9] Group 3: Research and Development Mechanisms - The Guangdong Nanotechnology Innovation Research Institute (广纳院) is shifting from a bottom-up approach to a top-down model, addressing industry needs directly to shorten marketization cycles [8] - The institute has developed various platforms for technology transfer, including clinical trial centers and performance testing centers, to support R&D and commercialization [9] - The institute has successfully nurtured several enterprises and raised significant funding, indicating a robust ecosystem for nanotechnology innovation [9]

Group 1 - The core viewpoint of the news is the performance and characteristics of the Hong Kong Dividend ETF (工银, 159691), which has shown a slight increase in scale and a decrease in shares since the beginning of the year [1] - As of February 6, 2023, the fund's latest share count is 6.275 billion, with a total scale of 8.653 billion yuan, reflecting a 3.90% decrease in shares and a 2.58% increase in scale since December 31, 2022 [1] - The fund's management fee is 0.45% annually, and the custody fee is 0.07% annually, with its performance benchmark being the adjusted return of the China Securities Hong Kong Stock Connect High Dividend Select Index [1] Group 2 - The current fund managers are Liu Weilin and He Shun, with Liu managing since March 30, 2023, achieving a return of 39.18%, while He is set to manage from May 30, 2024, with a return of 16.38% [2] - The fund's top holdings include China National Offshore Oil Corporation (14.55%), China Shenhua Energy Company (9.65%), and China Pacific Insurance (8.90%), among others, with significant market values [2][3] - The cumulative trading amount for the fund in the last 20 trading days is 7.145 billion yuan, with an average daily trading amount of 357 million yuan [1]

来源：新浪基金 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调近两个季度，长期看，较多优质标的估值性价 比明显，当前位置建议加大关注。* 再来看港股通医疗板块表现，AI医疗、脑机接口概念股较为活跃，大权重领衔涨势，京东健康、阿里 健康、平安好医生齐涨3%左右，港股通医疗ETF华宝（159137）日线五连阳。 目前AI医疗在C端的渗透正在加速，从智能问诊到慢病管理的应用场景不断拓展，推动阿里健康、京东 健康等港股互联网医疗平台价值重估。 中信建投证券指出，港股器械整体创新属性较强，部分企业的创新产品具有license-out或被并购的可 能。基本面维度，行业内部多数公司经营业绩持续改善，低估值投资价值凸显。事件方面，预计迈瑞医 疗、可孚医疗今年将在港股上市，港股医疗器械板块效应和投资机会或将增多。* 2月9日，港股市场全面反弹，港股医药板块延续修复行情。 信达生物拿下88.5亿美元BD大单，无意外全天领涨，最高涨至8.55%，收涨7.42%，龙头股大受提振， 百济神州涨超3%，石药集团、中国生物制药、三生制药集 ...